uniQure has made progress in advancing its gene therapy candidates, including AMT-130 for Huntington's disease; additional data from phase I/II study expected Q4 of 2023. Interim data from the phase I ...
uniQure reported positive interim results across phase 1/2 studies, using AMT-130 for the treatment of patients with Huntington's Disease, leading to an 80% slowing of disease progression. The company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback